John S. Tokarski

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

Drug Target, Preclinical Assays, Pharmacotherapy +19

The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants

John S. Tokarski, John A. Newitt, Chieh Ying J. Chang et al. · Cancer Research · 2006 · 677 citations · Full text

Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism

A. J. Hopfinger, Shen Wang, John S. Tokarski et al. · Journal of the American Chemical Society · 1997 · 413 citations

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 345 citations · Full text

Discovery of <i>N</i>-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

Gretchen M. Schroeder, Yongmi An, Zhen‐Wei Cai et al. · Journal of Medicinal Chemistry · 2009 · 276 citations · Full text

Orally Efficacious Inhibitor, Drug Target, Pharmacotherapy +21